Antigen Information

General Information of This Antigen (ID: TAR0AIJKM)
Antigen Name
Hepatocyte growth factor receptor (MET)
Gene Name
MET
Gene ID
4233
Synonym
HGF/SF receptor;Proto-oncogene c-Met;Scatter factor receptor;Tyrosine-protein kinase Met
Sequence
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEH
HIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMAL
VVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSAL
GAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPE
FRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL
TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS
AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEF
TTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFL
LDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGW
CHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK
TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVIT
SISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEF
AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVH
EAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPV
FKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL
LKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQ
IKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGS
CRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF
NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVL
SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF
VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF
TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCW
HPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVD
TRPASFWETS

    Click to Show/Hide
Family
Tyr protein family
Function
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of neuronal precursors, angiogenesis and kidney formation. During skeletal muscle development, it is crucial for the migration of muscle progenitor cells and for the proliferation of secondary myoblasts. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis.

    Click to Show/Hide
Uniprot Entry
MET_HUMAN
HGNC ID
HGNC:7029
KEGG ID
hsa:4233
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
A humanized anti-c-MET IgG2 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
SHR-1826
SHR9265
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
 ADC Info 
ADC Name Payload Target Linker ADC Info
AAJ8D6-Mc-Val-Cit-MMAE [1]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
AAJ8D6-D07-Val-Cit-PAB-MMAE [1]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
AAJ8D6-PY-Val-Cit-MMAE [1]
Monomethyl auristatin E
Microtubule (MT)
PY-VC-PABC
 ADC Info 
Anti-c-Met antibody
 Antibody Info 
ADC Name Payload Target Linker ADC Info
RC108
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
YL211
YL0010014
DNA topoisomerase 1 (TOP1)
VK*G-NHCH2-O linker
 ADC Info 
MHB042C [2]
MH30010008
DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
CKD-703
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
Anti-c-MET IgG2 mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
SHR-A1403
SHR152852
Microtubule (MT)
L2-MC
 ADC Info 
Anti-c-MET pH-dependent mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
MYTX-011
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MET lgG1
 Antibody Info 
ADC Name Payload Target Linker ADC Info
LgG1-Mc-Val-Cit-MMAE [1]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
Anti-MET mAb
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Anti-c-Met IgG-OXA [3]
Oxaliplatin
Human Deoxyribonucleic acid (hDNA)
Dipeptide-p-amidobenzyl alcohol linker
 ADC Info 
Anti-MET mAb Ab-10
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CN106188293A ADC-1 [4]
CN106188293A_ADC-136584232
Undisclosed
CN106188293A_ADC-1LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-2 [4]
CN106188293A_ADC-236584232
Undisclosed
CN106188293A_ADC-2LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-3 [4]
CN106188293A_ADC-336584232
Undisclosed
CN106188293A_ADC-3LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-4 [4]
CN106188293A_ADC-436584232
Undisclosed
CN106188293A_ADC-4LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-9 [4]
CN106188293A_ADC-936584232
Undisclosed
CN106188293A_ADC-9LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-12 [4]
CN106188293A_ADC-1236584232
Undisclosed
CN106188293A_ADC-12LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
Anti-MET mAb Ab-11
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CN106188293A ADC-13 [4]
CN106188293A_ADC-1336584232
Undisclosed
CN106188293A_ADC-13LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-14 [4]
CN106188293A_ADC-1436584232
Undisclosed
CN106188293A_ADC-14LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-15 [4]
CN106188293A_ADC-1536584232
Undisclosed
CN106188293A_ADC-15LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
Anti-MET mAb Ab-9
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CN106188293A ADC-5 [4]
CN106188293A_ADC-536584232
Undisclosed
CN106188293A_ADC-5LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-6 [4]
CN106188293A_ADC-636584232
Undisclosed
CN106188293A_ADC-6LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-7 [4]
CN106188293A_ADC-736584232
Undisclosed
CN106188293A_ADC-7LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-8 [4]
CN106188293A_ADC-836584232
Undisclosed
CN106188293A_ADC-8LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-10 [4]
CN106188293A_ADC-1036584232
Undisclosed
CN106188293A_ADC-10LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
CN106188293A ADC-11 [4]
CN106188293A_ADC-1136584232
Undisclosed
CN106188293A_ADC-11LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
 ADC Info 
Anti-MET mAb cIRCR201
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CIRCR201-dPBD [5]
Glucuronide-dPBD
Human Deoxyribonucleic acid (hDNA)
Iso-PEG5-beta-glucuronide
 ADC Info 
Anti-MET mAb hD12
 Antibody Info 
ADC Name Payload Target Linker ADC Info
HD12-SG3249 [6]
PBD dimer SG3249
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
HD12-SG3259 [6]
PBD dimer SG3259
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
HD12-SG3315 [6]
PBD dimer SG3315
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
HD12-SG3246 [6]
PBD dimer SG3246
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
HD12-SG3227 [6]
PBD dimer SG3227
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
cMET A1-8 IgG Fab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
alpha-cMET FDC-Duo5_P1 [7]
Duo5
Undisclosed
Undisclosed
 ADC Info 
alpha-cMET FDC-Duo5_P2 [7]
Duo5
Undisclosed
Undisclosed
 ADC Info 
alpha-cMET FDC-Duo5_C [7]
Duo5
Undisclosed
Undisclosed
 ADC Info 
alpha-cMET FDC-MMAE_C [7]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
alpha-cMET ADC-Duo5_P1 (lo DAR) [7]
Duo5
Undisclosed
Undisclosed
 ADC Info 
alpha-cMET ADC-Duo5_P1 (hi DAR) [7]
Duo5
Undisclosed
Undisclosed
 ADC Info 
Emibetuzumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
LY3343544 [8]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
Emibetuzumab-ADC-24-1 [9]
Emibetuzumab-ADC-24-1 payload
Undisclosed
Emibetuzumab-ADC-24-1 linker
 ADC Info 
Emibetuzumab-ADC-24-2 [9]
Emibetuzumab-ADC-24-2 payload
Undisclosed
Emibetuzumab-ADC-24-2 linker
 ADC Info 
Emibetuzumab-ADC-24-3 [9]
Emibetuzumab-ADC-24-3 payload
Undisclosed
Emibetuzumab-ADC-24-3 linker
 ADC Info 
Emibetuzumab-ADC-24-4 [9]
Emibetuzumab-ADC-24-4 payload
Undisclosed
Emibetuzumab-ADC-24-4 linker
 ADC Info 
Emibetuzumab-ADC-24-5 [9]
Emibetuzumab-ADC-24-5 payload
Undisclosed
Emibetuzumab-ADC-24-5 linker
 ADC Info 
Emibetuzumab-ADC-24-6 [9]
Emibetuzumab-ADC-24-6 payload
Undisclosed
Emibetuzumab-ADC-24-6 linker
 ADC Info 
Emibetuzumab-ADC-24-7 [9]
Emibetuzumab-ADC-24-7 payload
Undisclosed
Emibetuzumab-ADC-24-7 linker
 ADC Info 
Emibetuzumab-ADC-24-8 [9]
Emibetuzumab-ADC-24-8 payload
Undisclosed
Emibetuzumab-ADC-24-8 linker
 ADC Info 
Emibetuzumab-ADC-24-9 [9]
Emibetuzumab-ADC-24-9 payload
Undisclosed
Emibetuzumab-ADC-24-9 linker
 ADC Info 
Emibetuzumab-ADC-24-10 [9]
Emibetuzumab-ADC-24-10 payload
Undisclosed
Emibetuzumab-ADC-24-10 linker
 ADC Info 
Emibetuzumab-ADC-24-11 [9]
Emibetuzumab-ADC-24-11 payload
Undisclosed
Emibetuzumab-ADC-24-11 linker
 ADC Info 
Emibetuzumab-ADC-24-12 [9]
Emibetuzumab-ADC-24-12 payload
Undisclosed
Emibetuzumab-ADC-24-12 linker
 ADC Info 
Emibetuzumab-ADC-24-13 [9]
Emibetuzumab-ADC-24-13 payload
Undisclosed
Emibetuzumab-ADC-24-13 linker
 ADC Info 
ADC Name Payload Target Linker ADC Info
HAV ADC [10]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
MT-8633
SG3199 (SC-DR002)
Human deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
 ADC Info 
ADC Name Payload Target Linker ADC Info
LAV ADC [10]
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
 ADC Info 
PCM-MET01
 Antibody Info 
ADC Name Payload Target Linker ADC Info
PCM-MET01-MMAE [11]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
ADC Name Payload Target Linker ADC Info
REGN5093-M114
Maytansine derivative M24
Microtubule (MT)
SC-Val-Cit-PABC
 ADC Info 
SCAc-Met (1)xSCAc-Met (2)
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CN117337196A Compound94 [12]
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)
 ADC Info 
STI-D0606
 Antibody Info 
ADC Name Payload Target Linker ADC Info
C-met monoclonal antibody-drug conjugate [13]
Mertansine DM1
Microtubule (MT)
Undisclosed
 ADC Info 
ADC Name Payload Target Linker ADC Info
BYON3521
Seco-DUBA
Human deoxyribonucleic acid (hDNA)
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
 ADC Info 
Telisotuzumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Telisotuzumab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
telisotuzumab adizutecan
AMDCPT
DNA topoisomerase 1 (TOP1)
Adizutecan linker
 ADC Info 
ABT-700 (S238C)-PBD [14]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
 ADC Info 
ABT-700-Mc-Val-Cit-MMAE [1]
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 ADC Info 
37307297 ADC 15 [15]
FD-1
Undisclosed
Undisclosed
 ADC Info 
37307297 ADC 16 [15]
FD-1
Undisclosed
Undisclosed
 ADC Info 
37307297 ADC 17 [15]
FD-1
Undisclosed
Undisclosed
 ADC Info 
37307297 ADC 18 [15]
FD-1
Undisclosed
Undisclosed
 ADC Info 
37307297 ADC 19 [15]
FD-2
Undisclosed
Undisclosed
 ADC Info 
37307297 ADC 20 [15]
FD-3
Undisclosed
Undisclosed
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
SAB-Y14 [16]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
Hu-cMet 27Gv1.3 Hinge-L-DM21 [17]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
C-MET 0174 [18]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
APS-3010 [19]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
30kmPEG (SCAc-Met (1)xSCAc-Met (1))-2 (Val-Cit-PAB-DEA-SN38) [20]
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Undisclosed
 ADC Info 
References
Ref 1 Anti-c-met antibody-drug conjugate and applications thereof; 2022-03-10.
Ref 2 Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor
Ref 3 High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol. 2019 Aug 2;9:717. doi: 10.3389/fonc.2019.00717. eCollection 2019.
Ref 4 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof.
Ref 5 cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors. ACS Omega. 2020 Sep 29;5(40):25798-25809. doi: 10.1021/acsomega.0c03102.
Ref 6 TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3.
Ref 7 Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET
Ref 8 A novel molecule with profound tumor killing activity. Cancer Res (2019) 79 (13_Supplement): 353.
Ref 9 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.
Ref 10 Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals
Ref 11 MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res. 2020 Sep 22;39(1):198. doi: 10.1186/s13046-020-01711-x.
Ref 12 PEGylated antibody hydroxyl-bearing drug conjugates
Ref 13 Introduction to basic information on ADC drug C-met monoclonal antibody-drug conjugate
Ref 14 ANTI-cMet antibody drug conjugates and methods for their use; 2017-11-23.
Ref 15 Structure-Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody-Drug Conjugate Payloads
Ref 16 Syntab therapeutics biotechnology company product pipeline
Ref 17 Preclinical evaluation of a new, non-agonist ADC targeting MET-amplified tumors with a peptide-linked maytansinoid. Cancer Res (2019) 79 (13_Supplement): 4817.
Ref 18 c-Met Antibody Drug Conjugate.
Ref 19 Introduction to basic information on ADC drug APS-3010.
Ref 20 PEGylated antibody hydroxyl-bearing drug conjugates